載入中
NASDAQHealthcareBiotechnology
最新資料
US$20.5945
−US$0.4855 · -2.30%
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
一般交易時段
US$20.5945
−US$0.4855 · -2.30%
盤中時間採用ET。市場資料可能有所延遲。
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
日內區間
目前US$20.5945
52週區間
目前US$20.5945
盤中時間採用ET。市場資料可能有所延遲。
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
日內區間
目前US$20.5945
52週區間
目前US$20.5945
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 18.1萬 USD | 83萬 USD | 49萬 USD | 44.1萬 USD |
| 毛利 | — | −18.1萬 USD | −83萬 USD | −49萬 USD | −44.1萬 USD |
| 研究與開發 | 2.01億 USD | 639.8萬 USD | 2377萬 USD | 4820.6萬 USD | 3848.8萬 USD |
| 銷售、一般及管理費用 | 968.5萬 USD | 1031.8萬 USD | 1185.7萬 USD | 1251.1萬 USD | 1329.8萬 USD |
| 營業費用 | 2.11億 USD | 1671.6萬 USD | 3562.7萬 USD | 6071.7萬 USD | 5178.6萬 USD |
| 利息收入 | 116.7萬 USD | 84.4萬 USD | 168.9萬 USD | 72.2萬 USD | 15.6萬 USD |
| 折舊和攤銷 | 3.4萬 USD | 18.1萬 USD | 83萬 USD | 49萬 USD | 44.1萬 USD |
| 營業利益 | −2.11億 USD | −1689.7萬 USD | −3645.7萬 USD | −6120.7萬 USD | −5222.7萬 USD |
| 淨利 | −2.1億 USD | −2143.9萬 USD | −3834.9萬 USD | −6162.4萬 USD | −5175.2萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅3項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年8月30日 | 1:25 | — | — |
已生效 2024年8月30日
1:25
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM2608.72萬0.03%787.4億 USD0.19%US$278.45-0.18%
State Street SPDR S&P Biotech ETFXBI1508.02萬0.15%98.74億 USD0.35%US$152.97-0.52%
Vanguard Russell 2000 ETFVTWO864.8萬0.05%180億 USD0.06%US$112.48-0.16%
iShares Russell 2000 Growth ETFIWO636.41萬0.05%139.17億 USD0.24%US$355.2-0.44%
Vanguard Extended Market ETFVXF605.57萬0.01%954億 USD0.05%US$234.39-0.26%
Schwab U.S. Small-Cap ETFSCHA541.82萬0.02%218.24億 USD0.03%US$32.755-0.11%
iShares Core S&P Total U.S. Stock Market ETFITOT150.2萬0.00%980.88億 USD0.03%US$169.56-0.06%
Vanguard Russell 2000 Growth ETFVTWG113.48萬0.06%17億 USD0.06%US$259.28-0.47%iShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Core S&P Total U.S. Stock Market ETFITOTVanguard Russell 2000 Growth ETFVTWGAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
